Syros Pharmaceuticals develops medicines that control the expression of genes using a proprietary gene-control platform. The company’s platform identifies crucial genes that become dysregulated in diseased cells and is used to discover gene-control product candidates. Syros is building a pipeline focused on cancer and other serious diseases, with its lead program SY-1425 advancing toward clinical development. The company closed a $40M financing to support pipeline advancement. The funds will be used to advance a Phase 2 study of SY-1425, expected to begin in the first half of 2016 in a genomically defined subset of patients with acute myelogenous leukemia and myelodysplastic syndromes. Led by CEO Nancy Simonian, M.D., Syros is leveraging its platform to translate gene-control discoveries into therapeutic candidates. Syros Pharmaceuticals develops gene-control therapies by identifying and modulating master switches for disease genes. Its proprietary platform maps gene-control pathways directly in human disease tissue to discover therapeutics and biomarkers and to identify patients most likely to benefit. The company aims to advance its first program into the clinic in a molecularly defined patient population and to build a deep pipeline of gene-control product candidates. Syros plans to expand its gene control product engine into new therapeutic areas beyond oncology. Founded in 2013, the company and its founders have produced publications in Cell and Nature and were co‑founded by Flagship Ventures and ARCH Venture Partners. It recently strengthened its balance sheet by closing a $53 million Series B to support clinical advancement of its cancer programs. Syros Pharmaceuticals applies breakthroughs in gene control to discover medicines that target regulatory "switches" such as Super-Enhancers. Its proprietary platform identifies master switches for disease genes and aims to translate those discoveries into novel therapeutics. The company’s initial focus is cancer, with the platform positioned to be applicable to other therapeutic areas. Syros has executed exclusive, worldwide licensing agreements with the Whitehead Institute and the Dana‑Farber Cancer Institute covering its Super‑Enhancer technologies and methods. Management is led by CEO Nancy Simonian and includes experienced drug development and business leaders. Syros is co-founded and backed by ARCH Venture Partners and Flagship Ventures and is based in Watertown, MA.

Total raised

$123M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2016